leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Company profile
Ticker
CORT
Exchange
Website
CEO
Joseph Belanoff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
770487658
CORT stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Apr 24
ARS
2023 FY
Annual report to shareholders
17 Apr 24
8-K
Entry into a Material Definitive Agreement
17 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Corcept Therapeutics Announces Fourth Quarter Financial Results
15 Feb 24
8-K
Corcept Therapeutics Provides Financial Update
8 Jan 24
8-K
Court Finds Corcept Therapeutics’ Patents Not Infringed
2 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
11 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
Transcripts
CORT
Earnings call transcript
2023 Q4
15 Feb 24
CORT
Earnings call transcript
2023 Q3
1 Nov 23
CORT
Earnings call transcript
2023 Q2
2 Aug 23
CORT
Earnings call transcript
2023 Q1
3 May 23
CORT
Earnings call transcript
2022 Q4
28 Feb 23
CORT
Earnings call transcript
2022 Q3
4 Nov 22
CORT
Earnings call transcript
2022 Q2
4 Aug 22
CORT
Earnings call transcript
2022 Q1
6 May 22
CORT
Earnings call transcript
2021 Q4
16 Feb 22
CORT
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
DAVID L MAHONEY
12 Apr 24
4
Joseph Douglas Lyon
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Joseph Douglas Lyon
3 Apr 24
4
Daniel N Swisher JR
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Sean Maduck
29 Mar 24
SC 13G/A
INGALLS & SNYDER LLC
27 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Sean Maduck
20 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 111.80 mm | 111.80 mm | 111.80 mm | 111.80 mm | 111.80 mm | 111.80 mm |
Cash burn (monthly) | 20.19 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 138.20 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | -26.40 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | -1.3 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
78.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 243 |
Opened positions | 40 |
Closed positions | 20 |
Increased positions | 80 |
Reduced positions | 91 |
13F shares | Current |
---|---|
Total value | 1.98 tn |
Total shares | 81.55 mm |
Total puts | 238.60 k |
Total calls | 396.80 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 15.20 mm | $414.05 bn |
Vanguard | 9.30 mm | $253.31 bn |
Ingalls & Snyder | 8.34 mm | $227.23 mm |
Renaissance Technologies | 6.61 mm | $180.84 bn |
Parallel Advisors | 3.72 mm | $101.45 bn |
Novo Holdings A/S | 3.38 mm | $92.04 bn |
STT State Street | 3.14 mm | $85.63 bn |
Dimensional Fund Advisors | 2.31 mm | $62.89 bn |
Geode Capital Management | 1.96 mm | $53.34 bn |
Boston Trust Walden | 1.83 mm | $49.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | Mahoney David L | Common Stock | Other | Acquire J | Yes | No | 0 | 27,806 | 0.00 | 1,212,614 |
10 Apr 24 | Mahoney David L | Common Stock | Other | Dispose J | No | No | 0 | 27,806 | 0.00 | 27,806 |
10 Apr 24 | Mahoney David L | Common Stock | Payment of exercise | Dispose F | No | No | 23.8 | 2,194 | 52.22 k | 27,806 |
10 Apr 24 | Mahoney David L | Common Stock | Option exercise | Acquire M | No | No | 1.74 | 30,000 | 52.20 k | 30,000 |
10 Apr 24 | Mahoney David L | Stock option Common Stock | Option exercise | Dispose M | No | No | 1.74 | 30,000 | 52.20 k | 0 |
4 Apr 24 | Joseph Douglas Lyon | Common Stock | Sell | Dispose S | No | Yes | 26.0011 | 5,443 | 141.52 k | 7,314 |
4 Apr 24 | Joseph Douglas Lyon | Common Stock | Option exercise | Acquire M | No | No | 11.35 | 5,443 | 61.78 k | 12,757 |
4 Apr 24 | Joseph Douglas Lyon | Stock option Common Stock | Option exercise | Dispose M | No | No | 11.35 | 5,443 | 61.78 k | 37,224 |
1 Apr 24 | Daniel N Swisher JR | Common Stock | Sell | Dispose S | No | Yes | 25.3 | 2,200 | 55.66 k | 0 |
1 Apr 24 | Daniel N Swisher JR | Common Stock | Option exercise | Acquire M | No | No | 5.86 | 2,200 | 12.89 k | 2,200 |
News
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target
23 Apr 24
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
16 Feb 24
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having Hypercortisolism
15 Feb 24
Earnings Scheduled For February 15, 2024
15 Feb 24
Earnings Preview: Corcept Therapeutics
14 Feb 24